OBJECTIVES: The purpose of this analysis was to evaluate the correlation between atrial tachycardia (AT) or atrial fibrillation (AF) and clinical outcomes in heart failure (HF) patients implanted with a cardiac resynchronization therapy defibrillator (CRT-D). BACKGROUND: In HF patients, AT and AF have high prevalence and are associated with compromised hemodynamic function. METHODS:Forty-four Italian cardiological centers followed up 1,193 patients who received a CRT-D according to current guidelines for advanced HF, New York Heart Association functional class ≥ II, left ventricular ejection fraction ≤ 35%, and QRS complex ≥ 120 ms. All patients were in sinus rhythm at implant. RESULTS: During a median follow-up period of 13 months, AT/AF >10 min occurred in 361 of 1,193 (30%) patients. The composite end point (deaths or HF hospitalizations) occurred in 174 of 1,193 (14.6%). Multivariate time-dependent Cox regression analyses showed that composite end point risk was higher among patients with device-detected AT/AF (hazard ratio [HR]: 2.16, p = 0.032), New York Heart Association functional class III or IV compared with II (HR: 2.09, p = 0.002), and absence of beta-blockers (HR: 1.36, p = 0.036). Furthermore, the composite end point risk was inversely associated with left ventricular ejection fraction (HR: 1.04, p = 0.045), increasing by a factor of 4% for each 1% decrease in left ventricular ejection fraction. CONCLUSIONS: In HF patients with CRT-D, device-detected AT/AF is associated with a worse prognosis. Continuous device diagnostics monitoring and Web-based alerts may inform the physician of AT/AF occurrences and identify patients at risk of cardiac deterioration or patients with suboptimal rate or rhythm control. (Italian ClinicalService Project; NCT01007474).
RCT Entities:
OBJECTIVES: The purpose of this analysis was to evaluate the correlation between atrial tachycardia (AT) or atrial fibrillation (AF) and clinical outcomes in heart failure (HF) patients implanted with a cardiac resynchronization therapy defibrillator (CRT-D). BACKGROUND: In HF patients, AT and AF have high prevalence and are associated with compromised hemodynamic function. METHODS: Forty-four Italian cardiological centers followed up 1,193 patients who received a CRT-D according to current guidelines for advanced HF, New York Heart Association functional class ≥ II, left ventricular ejection fraction ≤ 35%, and QRS complex ≥ 120 ms. All patients were in sinus rhythm at implant. RESULTS: During a median follow-up period of 13 months, AT/AF >10 min occurred in 361 of 1,193 (30%) patients. The composite end point (deaths or HF hospitalizations) occurred in 174 of 1,193 (14.6%). Multivariate time-dependent Cox regression analyses showed that composite end point risk was higher among patients with device-detected AT/AF (hazard ratio [HR]: 2.16, p = 0.032), New York Heart Association functional class III or IV compared with II (HR: 2.09, p = 0.002), and absence of beta-blockers (HR: 1.36, p = 0.036). Furthermore, the composite end point risk was inversely associated with left ventricular ejection fraction (HR: 1.04, p = 0.045), increasing by a factor of 4% for each 1% decrease in left ventricular ejection fraction. CONCLUSIONS: In HF patients with CRT-D, device-detected AT/AF is associated with a worse prognosis. Continuous device diagnostics monitoring and Web-based alerts may inform the physician of AT/AF occurrences and identify patients at risk of cardiac deterioration or patients with suboptimal rate or rhythm control. (Italian ClinicalService Project; NCT01007474).
Authors: Alan S Go; Kristi Reynolds; Jingrong Yang; Nigel Gupta; Judith Lenane; Sue Hee Sung; Teresa N Harrison; Taylor I Liu; Matthew D Solomon Journal: JAMA Cardiol Date: 2018-07-01 Impact factor: 14.676
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Felix Hohendanner; F R Heinzel; F Blaschke; B M Pieske; W Haverkamp; H L Boldt; A S Parwani Journal: Heart Fail Rev Date: 2018-01 Impact factor: 4.214
Authors: Giovanni B Forleo; Luca Santini; Massimiliano Campoli; Mario Malavasi; Alberto Scaccia; Maurizio Menichelli; Umberto Riva; Filippo Lamberti; Giovanni Carreras; Serafino Orazi; Valentina Ribatti; Luigi Di Biase; Mariolina Lovecchio; Andrea Natale; Sergio Valsecchi; Francesco Romeo Journal: J Interv Card Electrophysiol Date: 2015-04-28 Impact factor: 1.900
Authors: Laura Perrotta; Brunilda Xhaferi; Marco Chiostri; Paolo Pieragnoli; Giuseppe Ricciardi; Luigi Di Biase; Andrea Natale; Ilaria Ricceri; Mazda Biria; Dhanunjay Lakkireddy; Alessandro Valleggi; Michele Emdin; Federica Michelotti; Giosuè Mascioli; Angela Pandozi; Massimo Santini; Luigi Padeletti Journal: Intern Emerg Med Date: 2012-12-19 Impact factor: 3.397
Authors: Mark S Link; Heike Luttmann-Gibson; Joel Schwartz; Murray A Mittleman; Benjamin Wessler; Diane R Gold; Douglas W Dockery; Francine Laden Journal: J Am Coll Cardiol Date: 2013-06-13 Impact factor: 24.094